ZBIO Company Profile and Key Details

NASDAQ : ZBIO

Zenas BioPharma

$29.43

0.665+2.31%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Zenas BioPharma, Inc. (ZBIO) stock surged +2.31%, trading at $29.43 on NASDAQ, up from the previous close of $28.77. The stock opened at $28.77, fluctuating between $28.76 and $30.00 in the recent session.

Stock Snapshot

28.765

Prev. Close

1.31B

Market Cap

28.76

Day Low

-5.85

P/E Ratio

-5.03

EPS (TTM)

N/A

Cash Flow per Share

28.77

Open

44.64M

Number of Shares

29.9999

Day High

24.48%

Free Float in %

N/A

Book Value

671.15K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 09, 2026	28.77	30.00	28.76	29.43	671.15K
Jul 08, 2026	27.36	28.84	26.55	28.77	795.85K
Jul 07, 2026	26.49	27.90	25.88	27.68	897.93K
Jul 06, 2026	26.90	27.54	26.41	26.45	605.32K
Jul 02, 2026	28.08	29.25	27.09	27.23	1.38M
Jul 01, 2026	25.49	29.00	25.48	28.00	2.34M
Jun 30, 2026	25.90	25.90	25.13	25.38	867.67K
Jun 29, 2026	25.87	25.94	24.76	25.55	1.25M
Jun 26, 2026	24.26	26.00	23.90	25.87	3.5M
Jun 25, 2026	21.96	24.92	21.94	24.67	1.59M
Jun 24, 2026	20.23	22.05	20.13	21.80	788.35K
Jun 23, 2026	20.54	21.25	20.18	20.20	513.35K
Jun 22, 2026	20.20	20.97	19.99	20.80	643.18K
Jun 18, 2026	18.93	19.88	18.72	19.78	2.13M
Jun 17, 2026	18.29	19.13	18.06	18.58	602.62K
Jun 16, 2026	18.76	19.43	17.87	18.19	392.13K
Jun 15, 2026	20.61	20.87	18.27	18.71	511.85K
Jun 12, 2026	17.78	20.10	17.77	19.80	1.32M
Jun 11, 2026	18.07	18.39	17.53	17.76	606.93K
Jun 10, 2026	18.42	19.00	17.74	17.91	432.8K

Contact Details

Waltham, MA 02451

United States

https://zenasbio.com 857 271 2954

About Company

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.

Stock Peers

ARGX

-5.81-0.63%

argenx SE$909.49 REGN

5.07+0.76%

Regeneron Pharmaceuticals, Inc.$667.95 MDGL

-5.39-0.95%

Madrigal Pharmaceuticals, Inc.$560.01 UTHR

-1.86-0.34%

United Therapeutics Corporation$552.48 VRTX

-1.93001-0.39%

Vertex Pharmaceuticals Incorporated$496.50 KRYS

-4.15999-1.11%

Krystal Biotech, Inc.$371.24 PRAX

0.13+0.04%

Praxis Precision Medicines, Inc.$333.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

7.73+2.45%

Ligand Pharmaceuticals Incorporated$322.61 ALNY

-10.70999-3.31%

Alnylam Pharmaceuticals, Inc.$312.79

Company Overview

Zenas BioPharma, Inc. (NASDAQ:ZBIO) closed at $29.43 USD, gaining $0.66 (2.31%) from the previous close of $28.77. The stock is currently mid-range between its 52-week high and low $10.42 and $44.60. With a market capitalization of about $1.31 billion, Zenas BioPharma, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.94). Key stats such as the average daily volume over the past year has been around 711.58 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Zenas BioPharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Leon Oliver Moulder Jr., the company employs approximately 167 people and listed since September 13, 2024. Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments.

Technical Performance

ZBIO has shown mixed momentum, gaining 5.56% over the past week and -12.82% over the past quarter, though year-to-date performance is down -42.5%. Short-term trend indicators are mixed aligned (SMA20 11.87%, SMA50 2.04%, SMA200 21.84%). The stock’s 14-day RSI is 57.39 (neutral), while the ATR of 2.13 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.9% below its high and over 331.42% above its low. Average 10-day trading volume of 1.10 million shares is significantly above the 3-month average of 700.29 thousand, indicating heightened recent market interest.

Valuation Metrics

Zenas BioPharma, Inc. trades at a P/E ratio of -3.21, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.85 trading at moderately above to book value. The P/FCF stands at -6.2, also below market averages.

Dividend & Fair Value

Zenas BioPharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.17. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 4.54% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 8 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $21.00. The high target offers 86.88% upside. The low target suggests -28.64% downside. The mean target is $39.94. This offers 35.71% upside. Zenas BioPharma, Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by -0.96%. The prior quarter beat by 9.85%. Over the last six quarters, Apple has recorded several small beats. These include 333.7% in March 25, 2025.

Shareholding & Insider Activity

Zenas BioPharma, Inc. has 42.11 million shares outstanding. The public float is 21.07 million shares, elevated short interest at 20.08% of float. This equals 5.76 million shares. The short ratio is 36.54 days. Institutional investors hold 122.7% of the float. Insiders own 23.2%. Fairmount Funds Management LLC holds 2.36 million shares, SR ONE CAPITAL MANAGEMENT, LLC has 1.17 million shares and Nunn Jason Raleigh has 1.17 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Zenas BioPharma has not generated any revenue.
On valuation metrics, Zenas BioPharma trades at a P/E of -3.21, P/S of 0.00 and P/B of 4.85. The current ratio is 11.94 and quick ratio is 11.94. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -67.96 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 1.05, supported by a cash flow-to-debt ratio of -0.60.

Price Forecast & Outlook

Our AI price prediction model suggests that Zenas BioPharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.89%, with price expected at $34.99 by July 22, 2026, within a range of $33.56 to $36.32 3-Month Outlook: Projected rise of 36.87%, reaching $40.28 by October 06, 2026, with a range of $39.28 to $41.16. 1-Year Outlook: Projected gain of 28.37%, with price at $37.78 by July 08, 2027, within a range of $35.23 to $40.52.

Key Takeaways

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shares are down -42.5% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Zenas BioPharma, Inc. trading at a premium to the broader market with a P/E of -3.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $37.69, suggesting 28.07% upside. Our AI forecast model points to short-term strength (18.89% over two weeks), a medium-term rise (36.87% over three months), and a longer-term gain (28.37% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Zenas BioPharma, Inc. (ZBIO) stock price?

Zenas BioPharma, Inc. (NASDAQ: ZBIO) stock price is $29.43 in the last trading session. During the trading session, ZBIO stock reached the peak price of $30.00 while $28.76 was the lowest point it dropped to. The percentage change in ZBIO stock occurred in the recent session was 2.31% while the dollar amount for the price change in ZBIO stock was $0.67.

ZBIO's industry and sector of operation?

The NASDAQ listed ZBIO is part of Biotechnology industry that operates in the broader Healthcare sector. Zenas BioPharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ZBIO?

No Data

How ZBIO did perform over past 52-week?

ZBIO's closing price is 182.44% higher than its 52-week low of $10.42 where as its distance from 52-week high of $44.60 is -34.01%.

How many employees does ZBIO have?

Number of ZBIO employees currently stands at 130.

Link for ZBIO official website?

Official Website of ZBIO is: https://zenasbio.com

How do I contact ZBIO?

ZBIO could be contacted at phone 857 271 2954 and can also be accessed through its website. ZBIO operates from North Building, Waltham, MA 02451, United States.

How many shares of ZBIO are traded daily?

ZBIO stock volume for the day was 671.15K shares. The average number of ZBIO shares traded daily for last 3 months was 711.58K.

What is the market cap of ZBIO currently?

The market value of ZBIO currently stands at $1.31B with its latest stock price at $29.43 and 44.64M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	130
Beta	-0.94
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

ZBIO Company Profile and Key Details

Zenas BioPharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics